P115 OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib with or without durvalumab in patients with BRCAm early-stage HER2-negative breast cancer

• J. Balmaña,
• M. Dymond,
• E.S. Lowe,
• N. Lukashchuk,
• M. Winter,
• N. Tung

Affiliations

J. Balmaña

M. Dymond

E.S. Lowe

N. Lukashchuk

M. Winter

N. Tung